Colorectal cancer
Conditions
Interventions
Low dose Group:hydromorphone 0.1mg/kg +nalmefene 3µg/kg +normal saline to 100ml
Ultra Low Dose Group:hydromorphone 0.1mg/kg +nalmefene 1µg/kg +normal saline to 100ml
Control Group:hydromorphone 0.1mg/kg +normal saline to 100ml
Sponsors
Peking University Shougang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-65 years; 2. 18 < BMI < 30; 3. ASA I - III patients; 4. Patients who underwent selective radical operation for colorectal cancer; 5. Patients who had signed the informed consent before the operation and voluntarily joined the study.
Exclusion criteria
Exclusion criteria: 1. Patients with preoperative nausea, vomiting and skin history; 2. Patients with serious liver and kidney dysfunction and other important organ diseases; 3. Patients with history of neuropsychiatric diseases; 4. Patients with a history of alcohol or opioid abuse; 5. Patients with allergic history of related drugs; 6. Patients who can't read or recognize VAS score and Ramsay grade correctly; 7. The patients who had used opioids, antiemetics and antipruritics in 24 hours before operation, and antidepressants or monoamine oxidase inhibitors in 15 days before operation; 8. Those who need to enter ICU for further treatment after operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain intensity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bolus frequency;analgesic rescue;Level of sedation;nausea;vomiting;antiemetic rescue;pruritus;Respiratory depression;Time to gastrointestinal recovery;Time to out-of-bed activity;Time to drainage tube removal;The duration of hospital stay;The degree of satisfaction with their pain management experience; | — |
Countries
China
Contacts
Public ContactZhenggang Guo
Peking University Shougang Hospital
Outcome results
None listed